Also Known As
Warfarin Sensitivity Genotyping
Formal Name
CYP2C9 Genotype; VKORC1 Genotype
This article was last reviewed on
This article waslast modified on May 1, 2019.
At a Glance
Why Get Tested?

To determine whether you have CYP2C9 and/or VKORC1 genetic variations and are likely to need lower, or less commonly, higher than average doses of the "blood-thinning" drug (anticoagulant) warfarin

When To Get Tested?

A health practitioner might order this test prior to prescribing warfarin for you; a health practitioner may sometimes order it when you are being treated with warfarin and have had bleeding or clotting episodes or dosing difficulties

Sample Required?

A blood sample drawn from a vein in your arm

Test Preparation Needed?

None

You may be able to find your test results on your laboratory's website or patient portal. However, you are currently at Lab Tests Online. You may have been directed here by your lab's website in order to provide you with background information about the test(s) you had performed. You will need to return to your lab's website or portal, or contact your healthcare practitioner in order to obtain your test results.

Lab Tests Online is an award-winning patient education website offering information on laboratory tests. The content on the site, which has been reviewed by laboratory scientists and other medical professionals, provides general explanations of what results might mean for each test listed on the site, such as what a high or low value might suggest to your healthcare practitioner about your health or medical condition.

The reference ranges for your tests can be found on your laboratory report. They are typically found to the right of your results.

If you do not have your lab report, consult your healthcare provider or the laboratory that performed the test(s) to obtain the reference range.

Laboratory test results are not meaningful by themselves. Their meaning comes from comparison to reference ranges. Reference ranges are the values expected for a healthy person. They are sometimes called "normal" values. By comparing your test results with reference values, you and your healthcare provider can see if any of your test results fall outside the range of expected values. Values that are outside expected ranges can provide clues to help identify possible conditions or diseases.

While accuracy of laboratory testing has significantly evolved over the past few decades, some lab-to-lab variability can occur due to differences in testing equipment, chemical reagents, and techniques. This is a reason why so few reference ranges are provided on this site. It is important to know that you must use the range supplied by the laboratory that performed your test to evaluate whether your results are "within normal limits."

For more information, please read the article Reference Ranges and What They Mean.

What is being tested?

Warfarin (Coumadin®) is a "blood-thinner" (anticoagulant), a drug that is commonly prescribed to help prevent inappropriate blood clotting (thrombosis and thromboembolism) in individuals who are at risk or to help keep an existing blood clotting condition from getting worse. Warfarin sensitivity testing helps determine if a person may be more sensitive (i.e., require lower doses) or, less commonly, resistant (i.e., require higher doses) to treatment with warfarin because of his or her genetic makeup. This test detects common genetic variations in two genes, CYP2C9 and VKORC1. A health practitioner may sometimes order this test to help select appropriate doses of warfarin and/or to achieve appropriate dose levels more quickly.

Warfarin can be a challenging drug to administer and monitor because its levels can be affected by many different factors and it has a narrow window in which it is effective. If a person is given too little drug, he or she may be at risk of forming a blood clot; if given too much drug, he or she may be at risk of moderate to severe bleeding episodes. The range between too much drug and too little drug is small and it varies significantly from person to person.

Historically, health practitioners have given warfarin doses based upon age, weight, and sex, and then have monitored and adjusted dosages using frequent PT/INR (prothrombin time/international normalized ratio) tests to determine the medication's anticoagulant ("blood-thinning") effect. Health practitioners then use periodic PT/INR tests to ensure that a stable dose with sufficient anticoagulation has been achieved. Although this dosing strategy is still commonly used, it can take as long as several weeks.

Genetic testing for warfarin sensitivity may help to shorten the time it takes for some people to reach a stable dose; that is, to achieve adequate "blood-thinning" without bleeding episodes. Most often, it is determined that people are more sensitive to warfarin and may need smaller doses; however, there are some people who are less sensitive and may need larger doses. The reason for the relative sensitivity can be, at least in part, due to the individual's genetic makeup and may involve two genes:

  • The VKORC1 gene codes for the production of a protein (VKOR) that is involved in the production of functional forms of certain clotting factors (II, VII, IX, X) that allows them to participate in the clotting process. Warfarin prevents the action of VKOR. Therefore, a variation in VKORC1 may cause someone to be more or less sensitive (or resistant) to warfarin.
  • The CYP2C9 gene codes for the production of a protein (CYP2C9) involved in the breakdown (metabolism) of warfarin. People with CYP2C9 variations may not be able to get the drug out of their system as efficiently as others. The people who clear the drug more slowly may require lower (sometimes significantly lower) doses of warfarin.

Each person receives one copy of each of their genes from their mother and one copy of each of their genes from their father. Thus, each of the CYP2C9 and VKORC1 genes is present in the body as two inherited gene copies (alleles). Any person could have both copies of a gene without any variants (wild-type); one copy without variants and one copy with a variant (heterozygous); both copies with the same variant (homozygous); and both copies with different variants ("compound heterozygous"). The combination of CYP2C9 and VKORC1 gene copies that a person has can determine the overall effect of warfarin and how rapidly it is metabolized and cleared from the body.

Warfarin sensitivity (or warfarin genotype) testing determines whether CYP2C9 and VKORC1 gene variants are present. Careful interpretation of the results can help the health practitioner decide the appropriate doses of warfarin for the person tested.

How is the sample collected for testing?

A blood sample is obtained by inserting a needle into a vein in the arm.

Is any test preparation needed to ensure the quality of the sample?

No test preparation is needed.

See More
See Less
Common Questions
  • How is it used?

    Warfarin sensitivity testing (genotyping) may be used to help determine someone's likely sensitivity or, less commonly, resistance to warfarin and to help select appropriate doses. Warfarin (Coumadin®) is an anticoagulant, a drug that is prescribed to help prevent inappropriate blood clotting (thrombosis and thromboembolism) in people who are at risk, or to help keep an existing blood clotting condition from getting worse.

    Warfarin genotyping identifies variations in certain genes.

    • The VKORC1 gene codes for the protein that warfarin targets. A variation in this gene may result in a protein change that may be more sensitive or less sensitive (or resistant) to the anticoagulant effect of warfarin. Depending on the variant present, the person tested may need a lower or higher initial dose of warfarin.
    • The CYP2C9 gene codes for a protein involved in the breakdown (metabolism) of warfarin. People with variations in this gene may metabolize warfarin more slowly, resulting in slower clearance of the drug and accumulation in the body over time. They may require a lower dose of the drug.

    This testing may sometimes be used to help determine an appropriate dose for a person who has previously taken warfarin and either experienced inappropriate clotting or bleeding episodes while on warfarin or had to go through many dose adjustments to reach a stable anticoagulant ("blood-thinning") effect.

    CYP2C9 and VKORC1 genetic testing is not widely used at this time. Although studies have shown that these genes contribute to a person's sensitivity to warfarin and can account for a significant percentage of the person-to-person variation in warfarin doses, there is not a consensus on the need for the testing yet.

  • When is it ordered?

    Warfarin sensitivity testing may be ordered prior to a person taking warfarin for the first time but may also be ordered when a person has had difficulties with achieving a stable anticoagulant ("blood-thinning") effect or has experienced either excessive blood clotting or bleeding.

    Not everyone who is prescribed warfarin will have this test done. At present, there is no consensus on the usefulness of this test and it is not yet widely accepted.

  • What does the test result mean?

    Warfarin sensitivity testing will identify the CYP2C9 and VKORC1 genetic variants (i.e., genotype) present for the person tested. The results must be interpreted carefully to help determine if the person is likely to need a relatively lower or higher dose of warfarin. These results are often interpreted by a specialist.

    Those who have one or more variant CYP2C9 or VKORC1 gene copies are more likely to need a lower or higher dose of warfarin. The amount needed will depend on the number and type of genetic variants present but will also greatly depend upon a person's other factors, including health, age, sex, diet, and other medications.

    This test detects only the most common genetic variants in CYP2C9 and VKORC1. A person may have a rare variant, resulting in a negative test result, but may still be more sensitive or resistant to warfarin.

  • Is there anything else I should know?

    Some major health organizations support warfarin sensitivity testing, while others would like to see more data showing that the use of the testing actually has an impact on the health of the patient, such as a decrease in the number of clotting or bleeding events experienced by those on warfarin. Currently, there are studies underway that may provide additional data on health outcomes in the next few years, and that is likely to help determine the clinical usefulness of testing.

    The U.S. Food and Drug Administration (FDA) has created changes to the warfarin label to provide information about the usefulness of CYP2C9 and VKORC1 genetic testing and to provide guidance on warfarin doses based upon testing results.

    Whatever the initial dosage of warfarin, each person taking warfarin will still need to be monitored with the PT/INR test and all subsequent dose adjustments will be made by taking these test results into account.

    Many drugs interact with warfarin and can slow the metabolism of warfarin. Make sure all of your healthcare providers are aware of all the medications you are taking.

    Warfarin is prescribed to those at risk for inappropriate clotting, including those who have had a previous blood clot; those with excessive clotting disorders, atrial fibrillation, artificial heart valves; and those who have undergone orthopedic surgeries.

  • If I have genetic testing done, will I still need to be monitored with PT/INR tests?

    Yes. Regardless of your genetic makeup, your response to warfarin therapy will still need to be monitored with regular PT/INR tests. This is because your individual degree of anticoagulation ("blood-thinning") can be affected by other factors such as diet, age, weight, other medications and state of health, which can change over time.

  • Can warfarin sensitivity testing be done in my doctor's office?

    No, it requires specialized equipment to perform and expertise to interpret. It is not offered by every laboratory and may need to be sent to a laboratory outside of your hospital (i.e., reference laboratory).

  • Will I need to have this test done more than once?

    No. This test determines information about the genes you have inherited. This information does not change so you will only need to be tested once.

  • Should I tell other doctors about my warfarin sensitivity?

    Yes, and you should always tell them that you are taking warfarin. The use of warfarin and your sensitivity to warfarin is important information for the medical professionals (including dentists) that you see. It can have an effect on your treatment options.

  • Should my other family members be tested for warfarin sensitivity?

    This is something to discuss with your healthcare provider and family. It is not generally indicated unless a family member is also going to be taking warfarin, but having a family member who has warfarin sensitivity is important information to keep in mind and to share with your health practitioner.

See More Common Questions See Less Common Questions
Related Content

On This Site

Tests: PT and INR, Pharmacogenetic Tests

Conditions: Excessive Clotting Disorders , Stroke, Heart Disease
Features: The Universe of Genetic Testing

Elsewhere On The Web

MedlinePlus: Warfarin
Mybloodthinner.org 
Human Genome Project: Phamacogenomics
National Institutes of Health: Medicines for You
Personalized Medicine Coalition
Mayo Clinic: Pharmacogenomics: When medicine gets personal
National Institute of General Medical Science: Frequently Asked Questions about Pharmacogenomics
American College of Chest Physicians: A Patient's Guide to Antithrombotic and Thrombolytic Therapy

See More
See Less
View Sources

Sources Used in Current Review

Chong, K. (2013 November 11, Updated). Warfarin Dosing and VKORC1/CYP2C9. Medscape Drugs and Diseases Available online at http://emedicine.medscape.com/article/1733331-overview through http://emedicine.medscape.com. Accessed 03/21/15.

(2013 November 19). Genetic data does not improve anticoagulation control with warfarin. National Heart Lung and Blood Institute Press Release Available online at http://www.nhlbi.nih.gov/news/press-releases/2013/genetic-data-does-not-improve-anticoagulation-control-with-warfarin through http://www.nhlbi.nih.gov. Accessed 03/21/15.

(2013 November 19). Genetic testing could improve warfarin dosing. American Heart Association Late-Breaking Clinical Trial Report LBCT 5/Abstract: 19658 (Hall E). American Heart Association. Available online at http://newsroom.heart.org/news/genetic-testing-could-improve-warfarin-dosing through http://newsroom.heart.org. Accessed 03/21/15.

Heikal, N. et. al. (2014 June, Updated). Warfarin Sensitivity. ARUP Consult. Available online at http://www.arupconsult.com/Topics/WarfarinSensitivity.html?client_ID=LTD through http://www.arupconsult.com. Accessed 03/21/15.

(2014 May).Warfarin Sensitivity (CYP2C9 and VKORC1) 3 Mutations. ARUP Laboratories. Available online at http://ltd.aruplab.com/Tests/Pdf/197 through http://ltd.aruplab.com. Accessed 03/21/15.

Hamberg, A. and Wadelius, M. (2014). Pharmacogenetics-Based Warfarin Dosing in Children. Medscape News and Perspective from Pharmacogenomics. 2014;15(3):361-374. Available online at http://www.medscape.com/viewarticle/821224 through http://www.medscape.com. Accessed 03/21/15.

Sources Used in Previous Reviews

Linnea M. Baudhuin, Ph.D., DABMG, Assistant Professor of Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Shah, S. and Voora, D. (Updated 2010 April 8). Warfarin Dosing and VKORC1/CYP2C9. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/1733331-overview through http://emedicine.medscape.com. Accessed May 2011.

Epstein, R. et. al. (2010 March 30). Warfarin Genotyping Reduces Hospitalization Rates Results From the MM-WES (Medco-Mayo Warfarin Effectiveness Study). J Am Coll Cardiol, 2010; 55:2804-2812 [On-line information]. Available online at http://content.onlinejacc.org/cgi/content/full/j.jacc.2010.03.009v1 through http://content.onlinejacc.org. Accessed May 2011.

Moyer, T. (2009 December). Warfarin Sensitivity Genotyping: A Review of the Literature and Summary of Patient Experience. Mayo Clinic Proceedings v 84 (12) 1079-1094 [On-line information]. Available online at http://www.mayoclinicproceedings.com/content/84/12/1079.full through http://www.mayoclinicproceedings.com. Accessed May 2011.

Mehra, M. (2010 March 16). MM-WES: Genetic testing for warfarin sensitivity linked with reduction in hospitalizations By American College of Cardiology 59th Annual Scientific Sessions. Cardiologytoday [On-line information]. Available online at http://www.cardiologytoday.com/view.aspx?rID=62016 through http://www.cardiologytoday.com. Accessed May 2011.

Bell, J. (2008 October). Experts Debate Pharmacogenetic Testing for Warfarin Sensitivity. Tests Could Enable Better Dosing, But Some Question the Data. AACC 2008 Annual Meeting Highlights, Clinical Laboratory News v 34 (10) [On-line information]. Available online at https://www.aacc.org/publications/cln/2008/october/Pages/am08_highlights1.aspx through https://www.aacc.org. Accessed May 2011.

(© 1995–2011). Mayo Medical Laboratories Unit Code 60529: Warfarin Sensitivity Genotype by Sequence Analysis, Blood [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/60529 through http://www.mayomedicallaboratories.com. Accessed May 2011.

Check, W. (2009 January). PGx tests for warfarin dosing—how soon? CAP Today [On-line information]. Available online through http://www.cap.org. Accessed May 2011.

Karp, J. (2010 March 1). SNP Testing for Warfarin Sensitivity. College of American Pathologists NewsPath [On-line information]. Available online through http://www.cap.org. Accessed May 2011.

Krautscheid, Patti et. al. (Updated 2010 June). Warfarin Sensitivity. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/WarfarinSensitivity.html?client_ID=LTD through http://www.arupconsult.com. Accessed May 2011.

Verhoef; T. et. al. (2010 September 17). Clinical and Economic Consequences of Pharmacogenetic-guided Dosing of Warfarin. Medscape Today from Expert Rev Pharmacoeconomics Outcomes Res. 2010;10(4):375-378. [On-line information]. Available online at http://www.medscape.com/viewarticle/727897 through http://www.medscape.com. Accessed May 2011.

Nainggolan, L. (2009 February 19). Prediction of Initial Dose of Warfarin Aided by Genetic Testing. Medscape News Today from Heartwire [On-line information]. Available online at http://www.medscape.com/viewarticle/588489 through http://www.medscape.com. Accessed May 2011.

(© 1994-2011). Warfarin (Rx) - Coumadin, Jantoven. Medscape Reference [On-line information]. Available online at http://reference.medscape.com/drug/coumadin-jantoven-warfarin-342182 through http://reference.medscape.com. Accessed May 2011.

(Updated 2011 May 13) Frequently Asked Questions About Pharmacogenomics. National Human Genome Research Institute [On-line information]. Available online at http://www.genome.gov/27530645 through http://www.genome.gov. Accessed May 2011.

Carlson, E. (2009 February 25). Web Exclusives: Genetics, Math Gives Blood. National Institute of General Medical Sciences [On-line information]. Available online at http://publications.nigms.nih.gov/computinglife/mathblood.htm through http://publications.nigms.nih.gov. Accessed May 2011.

Osinbawale O, et al. An algorithm for managing warfarin resistance. Cleveland Clinic Journal of Medicine December 2009 vol. 76 12 724-730. Available online at http://www.ccjm.org/content/76/12/724.full through http://www.ccjm.org. Accessed October 2011.

Bussey H, et al. Genetic Testing for Warfarin (Coumadin) Dosing? - Not Yet Ready for Prime Time. July, 2007 from Clot Care Online Resource.  Available online at http://www.clotcare.com/warfaringenetictesting.aspx through http://www.clotcare.com. Accessed October 2011.

Sconce E, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. October 1, 2005 vol. 106 no. 7 2329-2333. Available online at http://bloodjournal.hematologylibrary.org/content/106/7/2329.full through http://bloodjournal.hematologylibrary.org. Accessed October 2011.

See More
See Less

Ask a Laboratory Scientist

This form enables you to ask specific questions about lab tests. Your questions will be answered by a laboratory scientist as part of a voluntary service provided by one of our partners, American Society for Clinical Laboratory Science. Please allow 2-3 business days for an email response from one of the volunteers. 

Disclaimer
Thank you for using the Consumer Information Response Service ("the Service") to inquire about the meaning of your lab test results.  The Service is provided free of charge by the American Society for Clinical Laboratory Science, which is one of many laboratory organizations that supports Lab Tests Online.
Please note that information provided through this free Service is not intended to be medical advice and should not be relied on as such. Although the laboratory provides the largest single source of objective, scientific data on patient status, it is only one part of a complex biological picture of health or disease. As professional clinical laboratory scientists, our goal is to assist you in understanding the purpose of laboratory tests and the general meaning of your laboratory results. It is important that you communicate with your physician so that together you can integrate the pertinent information, such as age, ethnicity, health history, signs and symptoms, laboratory and other procedures (radiology, endoscopy, etc.), to determine your health status. The information provided through this Service is not intended to substitute for such consultations with your physician nor specific medical advice to your health condition.
By submitting your question to this Service, you agree to waive, release, and hold harmless the American Society for Clinical Laboratory Science and its affiliates or their past or present officers, directors, employees, agents, and Service volunteers (collectively referred to as "ASCLS") and the American Association  for Clinical Chemistry and its affiliates or their past or present officers, directors, employees, agents, and Service volunteers (collectively referred to as "AACC") from any legal claims, rights, or causes of action you may have in connection with the responses provided to the questions that you submit to the Service.
AACC, ASCLS and its Service volunteers disclaim any liability arising out of your use of this Service or for any adverse outcome from your use of the information provided by this Service for any reason, including but not limited to any misunderstanding or misinterpretation of the information provided through this Service.
 
See More See Less